Zevra therapeutics announces interim data from the phase 2 clinical trial of kp1077 for idiopathic hypersomnia

Data generated to date indicate sdx is well-tolerated across all doses and both dosing regimens studied, laying the groundwork for future phase 3 trial
ZVRA Ratings Summary
ZVRA Quant Ranking